Status:
COMPLETED
Interferon Responses in Eczema Herpeticum
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Atopic Dermatitis Research Network
Conditions:
Atopic Dermatitis
Eczema Herpeticum
Eligibility:
All Genders
6-65 years
Brief Summary
Atopic dermatitis (AD) is a chronic skin disorder characterized by recurrent viral skin infections. A small subset of patients with AD suffer from disseminated viral infections, e.g., eczema herpeticu...
Detailed Description
The investigators hypothesize that defective IFNγ responses in peripheral blood mononuclear cells (PBMCs) from ADEH+ patients results from aberrant pattern recognition receptors (PRR) signaling in ant...
Eligibility Criteria
Inclusion
- Participant
- Participants who meet all of the following criteria are eligible for enrollment:
- have a history of AD with or without a history of Eczema Herpeticum (EH) as diagnosed using the Atopic Dermatitis Research Network (ADRN) Standard Diagnostic Criteria OR
- -are non-atopic as diagnosed using the ADRN Standard Diagnostic Criteria
- are willing to sign the informed consent form or whose parent or legal guardian is willing to sign the informed consent form (age appropriate) prior to initiation of any study procedure
- are willing to sign the assent form, if age appropriate.
- Participant
Exclusion
- Participants who meet any of the following criteria are not eligible for enrollment:
- have a history of any systemic illness (e.g., immunodeficiency disorders such as human immunodeficiency virus \[HIV\] or lupus erythematosus) other than the condition being studied
- have an active systemic malignancy, excluding uncomplicated non-melanoma skin cancer
- have any skin disease other than AD that might compromise the stratum corneum barrier (e.g., bullous disease, psoriasis, cutaneous T cell lymphoma \[also called Mycosis Fungoides or Sezary syndrome\], dermatitis herpetiformis, Hailey-Hailey, or Darier's disease)
- have a first degree relative already enrolled in the study
- are determined not to be eligible in the opinion of the Investigator.
- Participants who meet any of the following criteria are not eligible for enrollment but may be reassessed:
- have active eczema herpeticum at the Enrollment Visit
- have taken systemic immunosuppressive drugs including cyclosporine or oral steroids within 30 days of the Enrollment Visit
- have a fever ≥ 38.5 degrees Centigrade (ºC) (101.3 ºF) at the Enrollment Visit.
Key Trial Info
Start Date :
April 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01429311
Start Date
April 1 2011
End Date
January 1 2016
Last Update
April 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Health
Denver, Colorado, United States, 80206